Clive Zent

20PUBLICATIONS
73CO-AUTHORS
Haematological tumoursHaematologyMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Medical bacteriology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Jul 09, 2026
Efficacy of high-frequency low-dose rituximab and acalabrutinib in chronic lymphocytic leukemia.

|Apr 14, 2026
Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant.

Clive S Zent, Enrico Tiacci, Robert J Kreitman

|Jan 02, 2025
Treatment of Relapsed/Refractory CLL Patients With PI3Kδ Inhibitor and Anti-CD20 Antibody Rapidly Decreases Tumor Burden but Could Induce Resistance.

Jennifer E Bruno, Christine A Herne, Andrea M Baran

|Oct 23, 2023
Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia.

Brian T Hill, Shuo Ma, Clive S Zent

|Mar 09, 2023
Arrhythmogenic Cardiotoxicity Associated With Contemporary Treatments of Lymphoproliferative Disorders.

Saadia Sherazi, Susan Schleede, Scott McNitt

|Jan 23, 2023
Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia.

Danielle S Wallace, Clive S Zent, Andrea M Baran

Pageof 4

Frequent Collaborators

5 joint publications

Sameer A Parikh

5 joint publications

Alessandro Gozzetti

5 joint publications

Paul M Barr

4 joint publications

Pier Luigi Zinzani